LONDON - AstraZeneca said Thursday that it intends to seek U.S. authorization for its COVID-19 vaccine in the second half of this year, offering a new timetable for the much-delayed application.The Anglo-Swedish drugmaker announced the schedule as it released second-quarter financial results, which showed that the company and its sub-licensees delivered more than 700 million doses of the vaccine to over 170 countries in the first half of this year.
That includes 80 million doses that went to the COVAX initiative for low- and middle-income countries.The news on the U.S. filing is being closely watched, as the timeframe has slipped.When AstraZeneca released data from its U.S.